logo flen pharma
Home   |  FAQ   |  research   |  scientific abstracts   |  distributors   |  contact info   |  vacancies   |  media library
Articles | Posters & Case Reports | Presentations


Cooper RA

Inhibition of biofilms by glucose oxidase, lactoperoxidase and guaiacol: the active antibacterial component in an enzyme alginogel.
Int Wound J. 2013, May 15. doi: 10.1111/iwj.12083. [Epub ahead of print]

The association of biofilms with wound chronicity has prompted a search for antimicrobial interventions that are effective against biofilms. A patented preparation of glucose oxidase, lactoperoxidase and guaiacol (GLG), which is the antibacterial component of Flaminal®, has been shown to inhibit a wide range of bacteria, but it has not yet been tested on biofilms. This study aims to determine the effect of GLG on biofilms of Staphylococcus aureus, methicillin-resistant S. aureus and Pseudomonas aeruginosa. Static biofilms were grown in microtitre plates and on coverslips and treated with a range of concentrations of GLG. Effects were monitored by estimating biofilm biomass by staining with crystal violet, biofilm activity by staining with either resazurin or fluorescein diacetate and biofilm viability by staining with LIVE/DEAD® BacLight Bacterial Viability Kit. GLG was able to prevent the formation of biofilms at concentration <e;0•5% (w/v) and higher concentrations were required to inhibit established biofilms. GLG did not disrupt biofilm biomass. Staphylococci were more susceptible to GLG than P. aeruginosa. These in vitro findings must be verified by in vivo studies.

return to articles
Articles | Posters & Case Reports | Presentations
Flaminal® Hydro | Flaminal® Forte | Flamigel® | Flamirins® | Extracalm®